According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
Several other brokerages have also recently issued reports on AUPH. SVB Leerink upped their target price on shares of Aurinia Pharmaceuticals from $24.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, January 27th. Cantor Fitzgerald upped their target price on shares of Aurinia Pharmaceuticals from $27.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, January 26th. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “buy” rating to an “accumulate” rating in a report on Tuesday, November 3rd. HC Wainwright upped their target price on shares of Aurinia Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Monday, January 25th. Finally, Royal Bank of Canada upped their target price on shares of Aurinia Pharmaceuticals from $20.00 to $28.00 and gave the company an “outperform” rating in a report on Tuesday, January 26th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.50.
NASDAQ AUPH opened at $16.79 on Monday. Aurinia Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $20.50. The stock has a market capitalization of $2.13 billion, a PE ratio of -11.42 and a beta of 0.87. The firm has a 50 day moving average of $14.65 and a two-hundred day moving average of $14.52.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Sunday, November 15th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Aurinia Pharmaceuticals had a negative net margin of 173,992.23% and a negative return on equity of 36.98%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.06 million. Sell-side analysts predict that Aurinia Pharmaceuticals will post -0.91 earnings per share for the current year.
Large investors have recently modified their holdings of the stock. Advisory Alpha LLC acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter worth $31,000. Lindbrook Capital LLC purchased a new position in Aurinia Pharmaceuticals during the 4th quarter worth $55,000. Parallel Advisors LLC raised its position in Aurinia Pharmaceuticals by 5,828.6% during the 4th quarter. Parallel Advisors LLC now owns 4,150 shares of the biotechnology company’s stock worth $57,000 after buying an additional 4,080 shares during the last quarter. Exane Derivatives raised its position in Aurinia Pharmaceuticals by 50.0% during the 3rd quarter. Exane Derivatives now owns 5,100 shares of the biotechnology company’s stock worth $75,000 after buying an additional 1,700 shares during the last quarter. Finally, Chiron Capital Management LLC purchased a new position in Aurinia Pharmaceuticals during the 3rd quarter worth $143,000. Hedge funds and other institutional investors own 51.21% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
See Also: Nikkei 225 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.